Following the leadership transition, Godrej Consumer Products Limited (GCPL) is addressing structural gaps to revive the core portfolio while accelerating momentum in newer initiatives. Aasif Malbari, the newly appointed CEO, has outlined his agenda anchored around four key thrust areas: category development, portfolio transformation, new-age FMCG transformation, and sustaining performance. The company is strengthening its relevance through deeper channel participation and sharper alignment with evolving media platforms, as reported by HDFC Securities Institutional Equities. This strategic focus comes as GCPL continues to maintain its FY27 guidance of high single-digit standalone volume growth, double-digit consolidated revenue growth and double-digit consolidated EBITDA growth, even as it looks to sharpen trade inventory management in India.
Multiple global brokerages have issued bullish outlooks for Godrej Consumer Products Limited (GCPL) following the company's recent strategic update. Emkay Global maintains a buy rating with a target price of ₹1,250, while Macquarie retains an Outperform rating with a target price of ₹1,100, and Morgan Stanley keeps an Equal-weight rating with a target price of ₹1,204. HDFC Securities Institutional Equities also maintains a Buy rating with a Sep-27 target price of ₹1,100, based on 37x P/E, set at a 20% discount to the five-year average forward P/E. The consensus reflects confidence in GCPL's FY27 targets despite near-term execution challenges, with all brokerages acknowledging the company's strong fundamentals and strategic positioning across multiple categories.
Under new leadership, GCPL is focusing on improving the growth trajectory of its core portfolio comprising soaps and household insecticides (HI) to rectify structural weaknesses over the last five years. The company believes household insecticides (HI) is a long-term opportunity, with category penetration rising from 65% to 80% over recent years, offering significant headroom for higher usage within households and premiumisation. GCPL is eyeing market share gains in burning formats on the back of its patented mosquito repellent molecule Renofluthrin (RNF), while looking at accelerating premium mosquito format upgrades through the right price point and robust execution. In skin cleansing, the company has been consistently gaining market share over the past decade, with share stabilising in the past three years, and has expanded beyond soaps through hand wash, face wash and foam body wash. The broader skin-cleansing market is expected to grow in high single digits, offering substantial runway for GCPL to build share beyond soaps.
To keep the portfolio refreshed and sustain outperformance, GCPL is investing more in research and development (₹150 crore) and distribution expansion and digital marketing (₹200 crore annually from FY28). The company is expanding the addressable market size by entering adjacent formats across various pests and focusing on premium innovations from G-lab to support its growth strategy. In hair colour, GCPL is looking at upgrading two-thirds of its users in traditional formats to cream/shampoo formats and subsequently premium hair colour. The company is also committed to investing in Home Care Liquids and will continue to invest in white spaces such as Pet Care. Across its global business, GCPL will fix the fundamentals in international businesses to build a "tunnel to the world" - the company gets nearly half of its revenue from global markets and has a presence in over 75 countries.
While maintaining bullish long-term outlooks, brokerages acknowledge near-term execution challenges. Morgan Stanley highlights that GCPL will execute an India inventory correction of ₹120-150 crore (roughly 1.5% of India sales) over the next three quarters to sharpen trade inventory management. This move is expected to introduce some near-term pressure but should be offset by improved performance in the international business. Motilal Oswal Research notes that organic unit volume growth for India and international operations stood at 4%, while organic sales growth was in the 6-7% range, as was operating profit growth. The brokerages signal that GCPL's ability to seamlessly execute its domestic strategy and protect its EBITDA margins will be the ultimate driver of the stock's performance heading into FY27.
